默克中国换帅，周虹履新诺和诺德！跨国药企中国区密集换帅背后的战略重构_老虎社区_美港股上老虎

默克中国换帅，周虹履新诺和诺德！跨国药企中国区密集换帅背后的战略重构

药厂那点事儿02-05

高端人才流动的轨迹，映射出跨国药企在中国战略调整的方向与决心。近日，默克中国发布两项重磅人事任命，罗杰仁重返中国担任默克中国总裁，该任命已于2026年2月1日正式生效。同时，穆安德正式出任默克中国医药健康业务董事总经理。此次调整中最引人注目的是周虹离开默克，加入诺和诺德担任全球产品与投资组合战略执行副总裁。周虹的离职与履新，成为近期跨国药企高管频繁变动中的标志性事件。默克中国管理层大调整默克中国...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

暂无评论

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2609314732?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-02-05 07:29","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2609314732","market":"us","top_or_hot":-1,"title":"默克中国换帅，周虹履新诺和诺德！跨国药企中国区密集换帅背后的战略重构","media":"药厂那点事儿","content":"<div>\n<p>高端人才流动的轨迹，映射出跨国药企在中国战略调整的方向与决心。近日，默克中国发布两项重磅人事任命，罗杰仁重返中国担任默克中国总裁，该任命已于2026年2月1日正式生效。同时，穆安德正式出任默克中国医药健康业务董事总经理。此次调整中最引人注目的是周虹离开默克，加入诺和诺德担任全球产品与投资组合战略执行副总裁。周虹的离职与履新，成为近期跨国药企高管频繁变动中的标志性事件。默克中国管理层大调整默克中国...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260205073640953fdcde&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>默克中国换帅，周虹履新诺和诺德！跨国药企中国区密集换帅背后的战略重构</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n默克中国换帅，周虹履新诺和诺德！跨国药企中国区密集换帅背后的战略重构\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-05 07:29 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260205073640953fdcde&s=b><strong>药厂那点事儿</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>高端人才流动的轨迹，映射出跨国药企在中国战略调整的方向与决心。近日，默克中国发布两项重磅人事任命，罗杰仁重返中国担任默克中国总裁，该任命已于2026年2月1日正式生效。同时，穆安德正式出任默克中国医药健康业务董事总经理。此次调整中最引人注目的是周虹离开默克，加入诺和诺德担任全球产品与投资组合战略执行副总裁。周虹的离职与履新，成为近期跨国药企高管频繁变动中的标志性事件。默克中国管理层大调整默克中国...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260205073640953fdcde&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0965509010.AUD","symbol_name":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (AUDHDG) INC","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260205073640953fdcde&s=b","article_id":"2609314732","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260205073640953fdcde&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2609314732","pubTimestamp":1770247768,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"近日，默克中国发布两项重磅人事任命，罗杰仁重返中国担任默克中国总裁，该任命已于2026年2月1日正式生效。周虹的离职与履新，成为近期跨国药企高管频繁变动中的标志性事件。跨国药企中国区密集换帅全景默克的人事变动只是跨国药企中国区换帅潮的一个缩影。2025年以来，超过十家跨国药企更换了中国区负责人。这些变动看似独立，实则共同勾勒出跨国药企应对中国市场深刻变革的战略调整。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0965509010.AUD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (AUDHDG) INC","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","NVO":"诺和诺德","SG9999001176.USD":"United Global Healthcare Acc USD","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","LU0965509283.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (SGDHDG) INC","BK4532":"文艺复兴科技持仓","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","BK4534":"瑞士信贷持仓","IE00BN8TJ469.HKD":"FTGF CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A\" (HKD) INC","LU0965509101.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (SGDHDG) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","BK4516":"特朗普概念","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU1066051225.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AC\" (USD) ACC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU1069347547.HKD":"AB SICAV I - GLOBAL VALUE PORTFOLIO \"AD\" (HKD) INC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","LU1917777945.USD":"安联专题基金Cl AT Acc","SG9999002232.USD":"Allianz Global High Payout USD","LU1699723380.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"AP\" (USD) ACC","SG9999002224.SGD":"Allianz Global High Payout SGD","SG9999015341.SGD":"United Income Focus Trust Acc SGD-H","LU0265550946.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A5\" (USD) INC","LU2361044949.HKD":"WELLINGTON US QUALITY GROWTH \"A\" (HKD) ACC","LU1934455863.HKD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (HKD) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","BK4585":"ETF&股票定投概念","SG9999014542.SGD":"United Income Focus Trust Acc SGD","LU1066051811.HKD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (HKD) INC","LU2360032135.SGD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (SGDHDG) INC","LU1201861249.SGD":"Natixis Harris Associates US Equity PA SGD-H","LU2361044865.SGD":"WELLINGTON US QUALITY GROWTH \"A\" (SGDHDG) ACC","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","LU0980610538.SGD":"Natixis Harris Associates US Equity RA SGD-H","LU1929549753.HKD":"FRANKLIN INCOME \"A\" (HKD) INC","LU2361045086.USD":"WELLINGTON US QUALITY GROWTH \"A\" (USD) ACC","LU0648001328.SGD":"Natixis Harris Associates US Equity RA SGD","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","BK4559":"巴菲特持仓","LU2125154935.USD":"ALLSPRING (LUX) WF GLOBAL EQUITY ENHANCED INCOME \"I\" (USD) INC","LU0058720904.USD":"联博国际健康护理基金A","BK4550":"红杉资本持仓","BK4588":"碎股","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1037948897.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (HKD) INC","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU0965508806.USD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (USD) INC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","LU0265550359.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A2\" (USD) ACC","LU1934455277.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"AD\" (USD) INC","LU1037948541.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (HKD) ACC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","SG9999014575.USD":"UOB UNITED INCOME FOCUS TRUST FUND (USDHDG) INC","BK4599":"减肥药","LU0985320562.USD":"NORDEA 1 GLOBAL STARS EQUITY \"BP\" (USD) ACC","LU0238689110.USD":"贝莱德环球动力股票基金","LU1941712264.USD":"ALLIANZ PET AND ANIMAL WELLBEING \"A\" (USD) INC","LU1116320737.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A6\" (USD) INC","LU1934455194.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (USD) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","NVOH":"Novo Nordisk A/S B Shares ADRhedged","LU2461242641.AUD":"WELLINGTON US QUALITY GROWTH \"A\" (AUDHDG) ACC","NVOX":"2倍做多NVO ETF-Defiance","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","MRK":"默沙东","LU1116320901.HKD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A6\" (HKD) INC","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","SG9999014559.SGD":"United Income Focus Trust Dis SGD","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","LU1035773651.USD":"AB SICAV I - GLOBAL VALUE PORTFOLIO \"AD\" (USD) INC","LU0098860793.USD":"FRANKLIN INCOME \"A\" INC","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU1941712348.USD":"ALLIANZ PET AND ANIMAL WELLBEING \"AT\" (USD) ACC","SG9999014567.USD":"UOB UNITED INCOME FOCUS TRUST FUND (USD) ACC","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","BK4007":"制药","LU2023250843.SGD":"Allianz Thematica Cl AT Acc H2-SGD","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","SG9999015358.SGD":"United Income Focus Trust Dis SGD-H","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","LU0130517989.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"R\" INC","LU0130102774.USD":"Natixis Harris Associates US Equity RA USD","LU2125154778.USD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (USD) INC","LU0861579265.USD":"联博低波幅策略股票基金A","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU0234572021.USD":"高盛美国核心股票组合Acc","LU0477156953.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"RE\" (USD) ACC"},"translate_title":"Merck changes coaching in China, Zhou Hong takes up the new Novo Nordisk! Strategic restructuring behind the intensive coaching changes of multinational pharmaceutical companies in China","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVOX":0.6,"NVOH":0.6,"MRK":1.85,"NVO":1.9},"content_text":"高端人才流动的轨迹，映射出跨国药企在中国战略调整的方向与决心。近日，默克中国发布两项重磅人事任命，罗杰仁重返中国担任默克中国总裁，该任命已于2026年2月1日正式生效。同时，穆安德正式出任默克中国医药健康业务董事总经理。此次调整中最引人注目的是周虹离开默克，加入诺和诺德担任全球产品与投资组合战略执行副总裁。周虹的离职与履新，成为近期跨国药企高管频繁变动中的标志性事件。默克中国管理层大调整默克中国此次人事调整涉及两个核心岗位。罗杰仁是默克老将，于2013年9月加入默克，曾执掌默克中国医药健康业务近五年。此次重返中国前，他担任默克拉丁美洲医药健康业务负责人及区域副总裁。同时，穆安德接替张巍出任默克中国医药健康业务董事总经理。穆安德从阿斯利康医药代表起步，2014年加入默克后持续进阶，2020年升任全球心血管代谢与内分泌业务高级副总裁。此次人事调整是默克全球管理层重组的一部分。2025年以来，默克先后任命了医药健康业务首席执行官、生命科学业务首席执行官等高层岗位。2026年5月1日，毕康明将正式接替现任CEO葛丽鹤，成为默克集团新任掌门人。周虹的职业轨迹与行业意义周虹在全球医药领域拥有逾30年的深耕经验，其职业发展轨迹在一定程度上反映了跨国药企战略重心的变化。周虹的职业生涯始于德勤咨询，随后在先灵、拜耳等企业担任财务、投资者关系及业务发展等职务。2015年3月，她出任罗氏制药中国总经理，在六年半内推动12款新药、22个新适应症在中国获批。在罗氏期间，她主导高价值靶向药物进入国家医保目录，使罗氏中国销售额实现翻番。2021年10月，周虹加入默克，担任医药健康全球执行副总裁、中国及国际市场负责人。在默克期间，她主导制定并落地默克中国五年战略规划，推动集团形成覆盖研发、制造、分销、销售及患者服务的全价值链布局。如今，周虹选择加入诺和诺德，担任全球产品与投资组合战略执行副总裁，这一职位变化体现了跨国药企对全球市场战略协调的重视。跨国药企中国区密集换帅全景默克的人事变动只是跨国药企中国区换帅潮的一个缩影。2025年以来，超过十家跨国药企更换了中国区负责人。2025年1月，武田中国宣布迎来全新的中国区总裁刘燕博士。5月，默沙东中国总裁田安娜卸任，由默沙东日本总裁Kyle Tattle接任。7月，BMS迎来新任中国总经理钱江。12月，勃林格殷格翰宣布大中华区负责人变更，高皓廷转任人药事业部新兴市场负责人。这一轮换帅潮涵盖了礼来、安斯泰来、诺华、GSK、默沙东、BMS、武田、默克等众多巨头。这些变动看似独立，实则共同勾勒出跨国药企应对中国市场深刻变革的战略调整。换帅潮背后的战略逻辑跨国药企中国区负责人频繁变动的背后，是中国医药市场的根本性变化。曾经推动跨国药企高速增长的市场环境已不复存在，取而代之的是医保谈判压价、集采冲击原研、本土创新药崛起的复杂局面。药企营销模式已从销售驱动、市场驱动转变为医学驱动和准入驱动。每个新产品的商业化过程都需要提前介入对产品的全面管理，营销策略的制定、产品定价、医保谈判等环节都需要充分筹备。中国区负责人的选拔标准也发生了显著变化。具有市场准入背景的高层管理者成为新趋势。如张巍和边欣等有市场准入背景的高管晋升至中国区负责人岗位，反映了这一转变。同时，跨区域管理经验成为重要考量因素。如默沙东的Kyle Tattle和诺华的李尧都是从日本市场调任中国，这体现了跨国药企希望将其他市场的管理经验应用于中国市场的战略意图。未来十年：从“商业化”到“战略化”跨国药企在中国的发展逻辑正在发生根本性转变。过去，中国区主要是全球商业架构的延伸，负责推广和放量。而现在，中国区正从“商业化团队”转变为“战略与能力双中心”。未来，中国区掌门人需要既懂中国的医药健康产业，又懂跨国药企的全球战略；既能面对政策不确定性，又能构建跨部门能力；既是生意人，又是“首席战略官”。跨国药企逐步意识到，在复杂支付体系、政策周期波动、高度分散的市场结构中生存下来的能力，本身就是一种新的全球战略资产。中国经验开始反向输出全球，成为跨国药企的核心竞争力之一。结语周虹从默克到诺和诺德的职业转变，不仅是个体生涯的发展，更是跨国药企全球战略调整的缩影。在日益复杂的中国医药市场，跨国药企不再满足于简单的销售增长，而是更加注重战略布局和本土化创新。未来，跨国药企在中国的竞争将不再仅仅是产品与渠道的竞争，更是战略思维、政策应对能力和生态系统构建能力的综合比拼。中国区掌门人的更迭不再是简单的人事变动，而是企业战略周期的重要标志，预示着跨国药企在中国发展模式的深刻变革。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}